CCR3


Also found in: Acronyms, Wikipedia.

CCR3

A gene on chromosome 3p21.3 that encodes a G protein-coupled receptor for C-C-type chemokines, including eotaxin (CCL11), eotaxin-3 (CCL26), MCP-3 (CCL7), MCP-4 (CCL13) and RANTES (CCL5). It is highly expressed in eosinophils and basophils, as well as in TH1 cells, TH2 cells and airway epithelial cells; it may contribute to the accumulation and activation of eosinophils and other inflammatory cells in airways allergies, and is also an entry co-receptor for HIV-1.
Segen's Medical Dictionary. © 2012 Farlex, Inc. All rights reserved.
References in periodicals archive ?
In a few instances [phrase omitted] is translated idiomatically with other CPA expressions, such as a possessive [phrase omitted] + pronominal suffix (Lk 1:36 CCR3; Jn 11:39 [Dama]).
Loetscher et al., "Eotaxin-2, a novel CC chemokine that is selective for the chemokine receptor CCR3, and acts like eotaxin on human eosinophil and basophil leukocytes," Journal of Experimental Medicine, vol.
* The report provides a snapshot of the global therapeutic landscape for C-C Chemokine Receptor Type 3 (C-C CKR-3 or Eosinophil Eotaxin Receptor or CD193 or CCR3)
Enhanced expression of eotaxin and CCR3 mRNA and protein in atopic asthma.
(10) Nonetheless, in our study recombinant UL128 could enhance the production of CCR1 as well as CCR3 and CCR4 at low concentration (10 ng/mL) which may correlate with its chemotactic function such as recruiting PMBC to the infectious site.
Wardlaw, and P Bradding, "Differential expression of CCR3 and CXCR3 by human lung and bone marrow-derived mast cells: implications for tissue mast cell migration," Journal of Leukocyte Biology, vol.
Eosinophils and CCR3 regulate interleukin-13 transgene-induced pulmonary remodeling.
RANTES [2] (which stands for regulated on activation, normal T-cell expressed and secreted) binds to CCR1, CCR3, CCR5, and DARC receptors and correspondingly has an integral role in inflammation, cell recruitment, and T-cell activation.
In a study, researchers at the University of North Carolina at Chapel Hill School of Medicine in collaboration with lead investigators at the University of Kentucky have demonstrated that blocking the activity of a specific protein - called CCR3 -- can reduce the abnormal blood vessel growth that leads to macular degeneration.